Indirect lymphography with iotrolan.
Identifieur interne : 005783 ( PubMed/Checkpoint ); précédent : 005782; suivant : 005784Indirect lymphography with iotrolan.
Auteurs : H. Partsch ; C. Stöberl ; M. Wruhs ; B I Wenzel-HoraSource :
- Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband [ 0178-4609 ] ; 1989.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Acides triiodo-benzoïques, Produits de contraste.
- imagerie diagnostique : Lymphoedème.
- Essais cliniques comme sujet, Humains, Iodo-benzoates, Lymphographie, Méthode en double aveugle, Relation dose-effet des médicaments.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Contrast Media, Triiodobenzoic Acids.
- diagnostic imaging : Lymphedema.
- Clinical Trials as Topic, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Iodobenzoates, Lymphography.
Abstract
Iotrolan was used in concentrations of 240 and 300 mg I/ml for indirect lymphography in a total of 70 patients, and permitted a diagnostic evaluation of the peripheral lymphatics in all cases. The contrast quality was found to correlate with the concentration used. The concentration of 300 mg I/ml Iotrolan was judged to provide the better contrast density and definition. Side effects were limited to transient local erythema and pain during the infusion in one patient and a protracted reaction resembling serum sickness in another patient (Iotrolan 240 mg I/ml). Because of its excellent tolerance, Iotrolan is particularly suitable after subepidermal infusion for indirect lymphography, during which the local lymph drainage of cutaneous regions of interest can be evaluated.
PubMed: 2568790
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:2568790Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Indirect lymphography with iotrolan.</title>
<author><name sortKey="Partsch, H" sort="Partsch, H" uniqKey="Partsch H" first="H" last="Partsch">H. Partsch</name>
</author>
<author><name sortKey="Stoberl, C" sort="Stoberl, C" uniqKey="Stoberl C" first="C" last="Stöberl">C. Stöberl</name>
</author>
<author><name sortKey="Wruhs, M" sort="Wruhs, M" uniqKey="Wruhs M" first="M" last="Wruhs">M. Wruhs</name>
</author>
<author><name sortKey="Wenzel Hora, B I" sort="Wenzel Hora, B I" uniqKey="Wenzel Hora B" first="B I" last="Wenzel-Hora">B I Wenzel-Hora</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1989">1989</date>
<idno type="RBID">pubmed:2568790</idno>
<idno type="pmid">2568790</idno>
<idno type="wicri:Area/PubMed/Corpus">006083</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">006083</idno>
<idno type="wicri:Area/PubMed/Curation">006083</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">006083</idno>
<idno type="wicri:Area/PubMed/Checkpoint">006083</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">006083</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Indirect lymphography with iotrolan.</title>
<author><name sortKey="Partsch, H" sort="Partsch, H" uniqKey="Partsch H" first="H" last="Partsch">H. Partsch</name>
</author>
<author><name sortKey="Stoberl, C" sort="Stoberl, C" uniqKey="Stoberl C" first="C" last="Stöberl">C. Stöberl</name>
</author>
<author><name sortKey="Wruhs, M" sort="Wruhs, M" uniqKey="Wruhs M" first="M" last="Wruhs">M. Wruhs</name>
</author>
<author><name sortKey="Wenzel Hora, B I" sort="Wenzel Hora, B I" uniqKey="Wenzel Hora B" first="B I" last="Wenzel-Hora">B I Wenzel-Hora</name>
</author>
</analytic>
<series><title level="j">Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband</title>
<idno type="ISSN">0178-4609</idno>
<imprint><date when="1989" type="published">1989</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Contrast Media (administration & dosage)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Humans</term>
<term>Iodobenzoates</term>
<term>Lymphedema (diagnostic imaging)</term>
<term>Lymphography</term>
<term>Triiodobenzoic Acids (administration & dosage)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acides triiodo-benzoïques (administration et posologie)</term>
<term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Iodo-benzoates</term>
<term>Lymphoedème (imagerie diagnostique)</term>
<term>Lymphographie</term>
<term>Méthode en double aveugle</term>
<term>Produits de contraste (administration et posologie)</term>
<term>Relation dose-effet des médicaments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Contrast Media</term>
<term>Triiodobenzoic Acids</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acides triiodo-benzoïques</term>
<term>Produits de contraste</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term>
<term>Dose-Response Relationship, Drug</term>
<term>Double-Blind Method</term>
<term>Humans</term>
<term>Iodobenzoates</term>
<term>Lymphography</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Essais cliniques comme sujet</term>
<term>Humains</term>
<term>Iodo-benzoates</term>
<term>Lymphographie</term>
<term>Méthode en double aveugle</term>
<term>Relation dose-effet des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Iotrolan was used in concentrations of 240 and 300 mg I/ml for indirect lymphography in a total of 70 patients, and permitted a diagnostic evaluation of the peripheral lymphatics in all cases. The contrast quality was found to correlate with the concentration used. The concentration of 300 mg I/ml Iotrolan was judged to provide the better contrast density and definition. Side effects were limited to transient local erythema and pain during the infusion in one patient and a protracted reaction resembling serum sickness in another patient (Iotrolan 240 mg I/ml). Because of its excellent tolerance, Iotrolan is particularly suitable after subepidermal infusion for indirect lymphography, during which the local lymph drainage of cutaneous regions of interest can be evaluated.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2568790</PMID>
<DateCreated><Year>1989</Year>
<Month>08</Month>
<Day>17</Day>
</DateCreated>
<DateCompleted><Year>1989</Year>
<Month>08</Month>
<Day>17</Day>
</DateCompleted>
<DateRevised><Year>2016</Year>
<Month>11</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0178-4609</ISSN>
<JournalIssue CitedMedium="Print"><Volume>128</Volume>
<PubDate><Year>1989</Year>
</PubDate>
</JournalIssue>
<Title>Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. Erganzungsband</Title>
<ISOAbbreviation>Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd</ISOAbbreviation>
</Journal>
<ArticleTitle>Indirect lymphography with iotrolan.</ArticleTitle>
<Pagination><MedlinePgn>178-81</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Iotrolan was used in concentrations of 240 and 300 mg I/ml for indirect lymphography in a total of 70 patients, and permitted a diagnostic evaluation of the peripheral lymphatics in all cases. The contrast quality was found to correlate with the concentration used. The concentration of 300 mg I/ml Iotrolan was judged to provide the better contrast density and definition. Side effects were limited to transient local erythema and pain during the infusion in one patient and a protracted reaction resembling serum sickness in another patient (Iotrolan 240 mg I/ml). Because of its excellent tolerance, Iotrolan is particularly suitable after subepidermal infusion for indirect lymphography, during which the local lymph drainage of cutaneous regions of interest can be evaluated.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Partsch</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
</Author>
<Author ValidYN="Y"><LastName>Stöberl</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wruhs</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wenzel-Hora</LastName>
<ForeName>B I</ForeName>
<Initials>BI</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd</MedlineTA>
<NlmUniqueID>0372776</NlmUniqueID>
<ISSNLinking>0178-4609</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007463">Iodobenzoates</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014283">Triiodobenzoic Acids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>16FL47B687</RegistryNumber>
<NameOfSubstance UI="C033300">iotrolan</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003287" MajorTopicYN="N">Contrast Media</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007463" MajorTopicYN="Y">Iodobenzoates</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008220" MajorTopicYN="Y">Lymphography</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014283" MajorTopicYN="Y">Triiodobenzoic Acids</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>1989</Year>
<Month>1</Month>
<Day>1</Day>
<Hour>0</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">2568790</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list></list>
<tree><noCountry><name sortKey="Partsch, H" sort="Partsch, H" uniqKey="Partsch H" first="H" last="Partsch">H. Partsch</name>
<name sortKey="Stoberl, C" sort="Stoberl, C" uniqKey="Stoberl C" first="C" last="Stöberl">C. Stöberl</name>
<name sortKey="Wenzel Hora, B I" sort="Wenzel Hora, B I" uniqKey="Wenzel Hora B" first="B I" last="Wenzel-Hora">B I Wenzel-Hora</name>
<name sortKey="Wruhs, M" sort="Wruhs, M" uniqKey="Wruhs M" first="M" last="Wruhs">M. Wruhs</name>
</noCountry>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005783 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 005783 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:2568790 |texte= Indirect lymphography with iotrolan. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:2568790" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |